- Report
- January 2026
- 193 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 181 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 181 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- March 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- October 2025
- 160 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- February 2022
- 180 Pages
Global
From €3897EUR$4,450USD£3,383GBP
Doripenem is an antibiotic used to treat a variety of bacterial infections. It belongs to the carbapenem class of antibiotics, which are broad-spectrum antibiotics used to treat serious infections caused by a wide range of bacteria. Doripenem is effective against both Gram-positive and Gram-negative bacteria, and is used to treat infections of the urinary tract, lower respiratory tract, skin, and soft tissue. It is also used to treat complicated intra-abdominal infections. Doripenem is administered intravenously and is generally well tolerated, with few side effects.
Doripenem is a relatively new antibiotic, and is not widely used. It is used mainly in hospitals, where it is used to treat serious infections that are resistant to other antibiotics. It is also used in combination with other antibiotics to treat infections that are difficult to treat.
Several companies are involved in the production and distribution of Doripenem. These include Merck & Co., Inc., Pfizer, Inc., AstraZeneca, and GlaxoSmithKline. Show Less Read more